Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	276
Overall Study	STARTED	Usual Care	137
Overall Study	Treated (Safety Population)	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	275
Overall Study	Treated (Safety Population)	Usual Care	137
Overall Study	ITT Population	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	273
Overall Study	ITT Population	Usual Care	136
Overall Study	ITT: Intent to Prescribe Fenofibrate	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	47
Overall Study	ITT: Intent to Prescribe Fenofibrate	Usual Care	24
Overall Study	COMPLETED	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	245
Overall Study	COMPLETED	Usual Care	129
Overall Study	NOT COMPLETED	Alirocumab 75 mg Q2W/Up to 150 mg Q2W	31
Overall Study	NOT COMPLETED	Usual Care	8

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02642159/flow